To cite: Yang Y, Zhou M,

Zhong X, et al. Dual versus

mono antiplatelet therapy

review and meta-analysis.

Additional material is

Received 31 May 2018

Accepted 31 May 2018

svn-2018-000168

2018-000168).

for acute non-cardioembolic

ischaemic stroke or transient

ischaemic attack: a systematic

Stroke and Vascular Neurology

2018;3: e000168. doi:10.1136/

published online only. To view

please visit the journal online

(http://dx.doi.org/10.1136/svn-

**()** Linked

http://dx.doi.org/10.1136/

Check for updates

svn-2018-000171

C Author(s) (or their

BMJ.

China

China

employer(s)) 2018. Re-use

permitted under CC BY-NC. No

commercial re-use. See rights

and permissions. Published by

Beijing Tiantan Hospital, Capital

Neurological Diseases, Beijing,

<sup>1</sup>Department of Neurology,

Medical University, Beijing,

<sup>2</sup>China National Clinical

<sup>3</sup>Center of Stroke, Beijing

Institute for Brain Disorders,

<sup>4</sup>Beijing Key Laboratory of

Translational Medicine for

**Research Center for** 

Stroke and Vascular Neurology

# Dual versus mono antiplatelet therapy for acute non-cardioembolic ischaemic stroke or transient ischaemic attack: a systematic review and meta-analysis

Yingying Yang,<sup>1,2,3,4</sup> Mengyuan Zhou,<sup>1,2,4,3</sup> Xi Zhong,<sup>1,2,4,3</sup> Yongjun Wang,<sup>1,2,4,3</sup> Xingquan Zhao,<sup>1,2,4,3</sup> Liping Liu,<sup>1,2,4,3</sup> Yilong Wang<sup>1,2,4,3</sup>

## ABSTRACT

**Objective** Recent years have seen new evidence on the efficacy and safety of dual antiplatelet therapy for secondary stroke prevention. We updated a meta-analysis of randomised controlled trials evaluating dual antiplatelet versus monotherapy for patients with acute noncardioembolic ischaemic stroke (IS) or transient ischaemic attack (TIA).

**Methods** We searched PubMed and identified randomised controlled trials evaluating dual antiplatelet versus monotherapy for acute non-cardioembolic IS or TIA within 3 days of ictus up to May 2018. Risk ratio (RR) with 95% Cl were calculated using random effects models. Clinical endpoints included stroke recurrence, composite vascular events and major bleeding.

**Results** 18 randomised controlled trials including 15515 patients were pooled in the meta-analysis. When compared with monotherapy among patients with acute IS or TIA, dual antiplatelet therapy reduced the risk of stroke recurrence (RR 0.69; 95% Cl 0.61 to 0.78; p<0.001) and composite vascular events (RR 0.72; 95% Cl 0.64 to 0.80; p<0.001). Dual therapy was associated with a significant increase in the risk of major bleeding (RR 1.77; 95% Cl 1.09 to 2.87; p=0.02) when all trial data were combined. However, when all previous trials before the completion of the POINT trial were analysed, dual antiplatelet versus monotherapy was not associated with a significant increase in the risk of major bleeding (RR 1.46; 95% Cl 0.77 to 2.75; p=0.25).

**Conclusions** Among patients with acute noncardioembolic IS or TIA within 3 days of ictus, dual antiplatelet therapy was associated with a reduction in stroke recurrence, and composite vascular events, when compared with monotherapy. However, a significant increase in the risk of major bleeding was observed.

#### **INTRODUCTION**

Acute minor ischaemic stroke (IS) and transient ischaemic attack (TIA) are very common and often lead to disabling events during the first few weeks.<sup>1</sup> Antiplatelet therapy can significantly reduce the risk of vascular events among high-risk patients. Current guidelines strongly recommend early administration of aspirin in patients with acute IS.<sup>2</sup> However, the efficacy and

safety of dual antiplatelet therapy have not been fully understood.

Over the past few decades, some large randomised controlled trials (RCT) have shown that dual antiplatelet therapy is more effective in reducing the risk of cerebral embolisation, including the CARESS trial (Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis) and CLAIR trial (Clopidogrel plus aspirin vs aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis).<sup>3 4</sup> The CHANCE trial (Clopidogrel in High-Risk Patients with Acute Non-Disabling Cerebrovascular Events) further demonstrated that early dual antiplatelet therapy for 21 days among 5170 Chinese patients with non-cardioembolic IS or TIA was efficacious and safe.<sup>56</sup>

A previous meta-analysis including 9012 patients from CHANCE and 13 other RCTs up to November 2012 showed that early dual versus mono antiplatelet therapy within 3 days of symptom onset was more effective in reducing stroke recurrence (risk ratio (RR) 0.69; 95% CI 0.60 to 0.80; p<0.001) and the composite outcome of stroke, TIA, acute coronary syndrome and all death (RR 0.71; 95% CI 0.63 to 0.81; p<0.001), without significantly increasing the risk of major bleeding (RR 1.35; 95% CI 0.70 to 2.59, p=0.37).<sup>7</sup> The 2018 American Heart Association/American Stroke Association (AHA/ASA) guidelines recommend the combination of clopidogrel and aspirin among patients with minor IS or TIA for early secondary stroke prevention (Class of recommendation: II A).<sup>2</sup> However, considering that the generalisability of the intervention in non-Asian populations remains unclear, the use of dual antiplatelet therapy was only modestly recommended.

Five years after the results of CHANCE were published, POINT (Platelet-Oriented

Cerebrovascular Disease, Beijing, China

Beijing, China

#### **Correspondence to**

Professor Yilong Wang; yilong528@aliyun.com





Inhibition in New TIA and Minor Ischemic Stroke), a large double-blind RCT aiming to test the dual antiplatelet therapy with clopidogrel plus aspirin worldwide, has recently published its results.<sup>8 9</sup> Therefore, in order to fully explore the efficacy and safety of early dual antiplatelet therapy for secondary stroke prevention, we updated the previous systematic review and meta-analysis of dual versus mono antiplatelet therapy for patients with acute non-cardioembolic IS or TIA within 3 days of symptom onset.<sup>7</sup>

## **METHODS**

#### Search strategy

We updated the previous systematic review and meta-analvsis published in *Circulation* in 2013<sup>7</sup> and 14 eligible studies up to November 2012 were included in this current meta-analysis. We also identified RCTs evaluating dual versus mono antiplatelet therapy for acute non-cardioembolic IS or TIA from November 2012 to May 2018. We searched PubMed and other databases with search words of 'antiplatelet therapy', 'aspirin', 'clopidogrel', 'cilostazol', 'dipyridamole', 'ticlopidine', 'prasugrel', 'triflusal', 'glycoprotein IIb/IIIa receptor antagonists', 'ticagrelor', 'stroke', 'cerebral ischemia', 'cerebral infarction', 'TIA', 'transient ischemic attack', 'randomized controlled trial' and 'randomized trial'. We also performed manual search of references from original articles and pertinent reviews. Searches were restricted to completed trials in human beings and English.

## **Selection criteria**

Two independent authors (YY and MZ) selected all studies. Inclusion criteria for the studies were: (1) RCT in design; (2) dual versus mono antiplatelet therapy was assessed in adult patients ( $\geq$ 18 years) with non-cardioembolic IS or TIA; (3) enrolment and randomisation of all or at least a portion of the patients was within 3 days of the index event; (4) at least one of clinical endpoints was assessed, including stroke recurrence, composite vascular events or major bleeding. Stroke recurrence was mostly defined as ischaemic or haemorrhagic stroke. Composite vascular events were mostly defined as the composite of stroke, TIA, myocardial infarction and death from cardiovascular causes. Major bleeding was mostly defined in accordance with moderate to severe bleeding by the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries definition.<sup>10</sup>

## Data extraction and quality assessment

First, for studies published from November 2012 to May 2018, study quality was independently assessed and data were extracted by two authors (YY and XZ) with the supervision from other authors (YW, XZ, LL). We also repeated data extraction from the 14 studies included in the previous meta-analysis. Unpublished subgroup data from these 14 studies were used directly from the previous meta-analysis. The following data were extracted: publication characteristics, countries or regions of the study,

study centres, blinding, enrolled populations, sample size randomised within 3 days of ictus, treatment groups, onset-to-treatment interval, severity of stroke, treatment duration for dual therapy, quality scale, intention-to treat analysis, completeness of follow-up, and efficacy and safety outcomes. The efficacy outcomes evaluated were stroke recurrence and composite vascular events. The safety outcome was major bleeding.

#### Data synthesis and analysis

Primary analyses were performed for each outcome, with trials subdivided by the different medications assessed. RR and 95% CIs were calculated using random effects models because the interventions, event rates and trial designs were expected to vary. We performed a sensitivity analysis by restricting the analysis to double-blind studies, to test whether the results of the present meta-analysis were sensitive to certain restrictions on the data included. Between-study and between-subgroup heterogeneities were evaluated by calculating the I<sup>2</sup> statistic and the Cochrane Q ( $\chi^2$ ) statistic. Publication bias of studies with different sample sizes was assessed by performing funnel plots. Two-sided probability values of <0.05 were considered statistically significant. All data were analysed using Cochrane Review Manager (V.5.3).

#### RESULTS

#### Selection process and study characteristics

All 14 studies in the previous meta-analysis were included.<sup>3 4 6 11-21</sup> For updated relevant studies from November 2012 to May 2018, database searching and citation tracking of references identified 691 publications (online supplementary figure 1). By reviewing title and abstract, 672 articles were excluded. Nineteen articles were reviewed by full text for details, and 15 of them were excluded: not dual versus mono antiplatelet therapy (n=6), no within 3 days of ictus (n=2), not exact onset-to-treatment interval (n=2), not clinical endpoints (n=1) and duplications (n=4). Therefore, four eligible RCTs published after November 2012 were identified, including POINT 2018, COMPRESS 2016, He et al (2015) and Yi *et al* (2014).<sup>9 22-24</sup> All of them compared clopidogrel plus aspirin versus aspirin alone in patients with acute non-cardioembolic IS or TIA.

In total, there were 18 studies with 15515 patients in the present meta-analysis (table 1), among which 9 were double blind, 11 were intention to treat and 15 had concealed allocation. Six trials enrolled patients with IS only<sup>12151921224</sup>, one trial enrolled patients with TIA only<sup>11</sup> and the others enrolled both patients with IS and TIA. Seven trials focused on minor stroke.<sup>4 6 9 17 18 21 23</sup> Onsetto-treatment intervals were  $\leq 1$  day in five trials,<sup>6 9 16 18 20</sup>  $\leq 2$ days in four trials<sup>15 21 22 24</sup> and  $\leq 3$  days in the other trials. For those trials that had a recruitment window extending beyond 3 days after the index event, we only used data from those patients recruited and randomised within the 3-day time window.<sup>3 13 14 16 17</sup>

Table 1 Des	sign and baseline chara	acteristics of included	trials									
Trial	Dual therapy	Monotherapy	Duration for dual therapy	Treatment onset	Patients	Severity of stroke	Country	Size (<3 days)	Blinding	ITT analysis	Lost to follow- up (%)	Quality
POINT 2018 <sup>9</sup>	Clop (600 mg load, 75 mg once daily)+Asp (50- 325 mg once daily)	Asp	3 months	≤12hours	Minor IS, TIA	NIHSS≤3	Worldwide, 269 centres	4881	Double blind	E	6.6	A
COMPRESS 2016 <sup>22</sup>	Clop (75mg once daily without load)+Asp (300mg load, 100mg once daily)	Asp	30 days	≤2 days	S	UNK	Korea, 20 centres	358	Double blind	E	6.7	A
He <i>et al</i> <sup>23</sup>	Clop (300 mg load, 75 mg once daily)+Asp (100 mg once daily)	Asp (300 mg once daily)	14 days	≤3 days	Minor IS, TIA	NIHSS ≤7	China, single centre	690	UNK	Analysed as treated	6.2	A
Yi et al <sup>24</sup>	Clop (75 mg once daily)-Asp (200 mg) for 30 days, then Clop alone (75 mg once daily)	Asp (200 mg once daily for 30 days, then 100 mg once daily)	30 days	≤2 days	ល	NIHSS ≤12	China, two centres	574	Blinded outcome	Analysed as treated	0.7	A
CHANCE 2012 <sup>6</sup>	Clop (300 mg load, 75 mg once daily)+Asp (75– 300 mg load, 75 mg once daily) for 21 days, then Clop alone (75 mg)	Asp (75–300 mg load, 75 mg once daily) for 3 m	21 days	≤24 hours	Minor IS, TIA	NIHSS 53	China, 114 centres	5170	Double blind	Ē	0.7	۲
Nakamura <i>et al</i> 21	Cilo (100 mg twice daily)+Asp (300 mg, then 100 mg once daily)	Asp	6 months	≤2 days	Minor IS	NIHSS ≤7	Japan, single centre	76	UNK	On-treatment analysis	16.7	В
CLAIR 2010 <sup>4</sup>	Clop (300 mg load, 75 mg once daily)+Asp (75– 160 mg once daily)	Asp	7 days	≤3 days	Minor IS, TIA	NIHSS ≤8	Asia, multicentres	98	Blinded outcome	E	1.0	A
PRoFESS 2009 <sup>19</sup>	Dip (200 mg twice daily)+Asp (25 mg twice daily)	Clop (75mg once daily)	3 months	≤3 days	S	mRS 0-3	Worldwide, 695 centres	1360	Double blind	Ш	0.9	A
EARLY 2009 <sup>20</sup>	Dip (200 mg twice daily)+Asp (25 mg twice daily) for 3 months	Asp (100 mg once daily) for 7 days, then Dip (200 mg twice daily)+Asp (25 mg twice daily)	3 months	≤24 hours	IS, TIA	NIHSS ≤20	Germany, 46 centres	543	Blinded outcome	Analysed as treated	2.9	۲
FASTER 2007 <sup>18</sup>	Clop (300 mg load, 75 mg once daily)+Asp (162 mg, then 81 mg once daily)	Asp	3 months	≤24 hours	Minor IS, TIA	NIHSS ≤3	North America, 18 centres	392	Double blind	E	1.8	A
ESPRIT 2006 <sup>17</sup>	Dip (200 mg twice daily)+Asp (30– 325 mg once daily)	Asp	42 months	≤3 days	Minor IS, TIA	mRS ≤3	Worldwide, 86 centres	95	Open	E	3.8	A
CHARISMA 2006 <sup>16</sup>	Clop (75mg once daily)+Asp (75– 162mg once daily)	Asp	28 months	≤24hours	IS, TIA	UNK	Worldwide, 768 centres	216	Double blind	Ē	≤0.5	A
Chairangsarit et al <sup>15</sup>	Dip (225 mg once daily)+Asp (300 mg once daily)	Asp	6 months	≤2 days	S	UNK	Thailand, single centre	38	Open	UNK	UNK	A
CARESS 2005 <sup>3</sup>	Clop (300 mg load, 75 mg once daily)+Asp (75 mg once daily)	Asp	7 days	≤3 days	IS, TIA	NIHSS 22	Europe, 11 centres	25	Double blind	E	0	A
								l			Co	ntinued

Stroke Vasc Neurol: first published as 10.1136/svn-2018-000168 on 26 June 2018. Downloaded from http://svn.bmj.com/ on June 22, 2025 by guest. Protected by copyright.

6

Table 1	Continued											
Trial	Dual therapy	Monotherapy	Duration for dual therapy	Treatment onset	Patients	Severity of stroke	Country	Size (<3 days)	Blinding	ITT analysis	Lost to follow- up (%)	Quality
MATCH 2004 <sup>14</sup>	Clop (75 mg once daily)+Asp (75 mg once daily)	Clop	18 months	≤3 days	IS, TIA	mRS 0-5	Worldwide, 507 centres	491	Double blind	Ē	4	A
ESPS 2 1996 <sup>13</sup>	Dip (200 mg twice daily)+Asp (25 mg twice daily)	Asp or Dip	24 months	≤3 days	IS, TIA	mRS 0-5	Europe, 59 centres	221	Double blind	Ē	0.64	٩
Kaye <sup>12</sup>	Dip+Asp (900mg once daily)	Asp	UNK	≤3 days	ខ	UNK	UNK	178	UNK	UNK	UNK	В
Matías-Guiu	<i>i et al</i> Dip (100 mg four times daily)+Asp (50 mg once daily)	Dip	21.4	≤3 days	TIA	UNK	Spain, single centre	109	Open	UNK	4.5	в
Quality scal Asp, aspirin;	e: A, true randomisation and alloc Cilo, cilostazol; Clop, clopidogre	cation concealed; B, process el; Dip, dipyridamole; IS, isch	of randomisatio aemic stroke; IT	n not given and T intention to tr	l concealmer eat; mRS, m	it of allocation odified Rankin	unclear. Scale; NIHSS, Nat	ional Institute	s of Health St	roke Scale; TIA,	transient ischaer	jc

attack: UNK. unknown.

<u>6</u>

The following antiplatelet medications were assessed in the meta-analysis: aspirin+clopidogrelversus aspirin (nine trials with 12404 patients)<sup>3 4 6 9 16 18 22-24</sup>; aspirin+clopidogrelversus clopidogrel (one trial with 491 patients)<sup>14</sup>; aspirin+dipyridamole versus aspirin (five trials with 964 patients)<sup>12</sup> 13 15 17 20; aspirin+dipyridamole versus dipyridamole (two trials with 220 patients)<sup>11</sup><sup>13</sup>; aspirin+dipyridamole versus clopidogrel (one trial with 1360 patients)<sup>19</sup>; and cilostazol+aspirin versus aspirin (one trial with 76 patients).<sup>21</sup> The European Stroke Prevention Study 2 investigated the combination of aspirin and dipyridamole against aspirin alone and dipyridamole alone, and the other studies each investigated one antiplatelet in the monotherapy group. No studies involving prasugrel, ticlopidine, ticagrelor or triflusal were identified.

# Synthesis of results

For analyses of efficacy and safety outcomes, no evidence existed for between-study or between-subgroup heterogeneities by the Cochrane Q statistic and the  $I^2$  statistic. No significant publication bias was identified by visual inspection of asymmetry of the funnel plots.

Sixteen studies had data regarding the efficacy outcome of stroke recurrence. In these 16 studies with different follow-up durations, dual antiplatelet therapy reduced the risk of stroke recurrence by  $\approx 30\%$  in patients with acute IS or TIA, as compared with monotherapy (RR 0.69; 95% CI 0.61 to 0.78; p<0.001; figure 1). Eleven studies had data regarding the composite vascular events. Among these 11 studies, dual antiplatelet therapy significantly reduced the risk of the composite vascular events by  $\approx 30\%$  in patients with acute IS or TIA randomised within 3 days of ictus, when compared with monotherapy (RR 0.72; 95% CI 0.64 to 0.80; p<0.001; figure 2).

Fourteen studies had data regarding the safety outcome of major bleeding. When all trial data were combined, major bleeding occurred in 0.65% and 0.33% of patients in the dual and monotherapy groups, respectively. As compared with mono antiplatelet therapy, dual therapy for patients with acute IS or TIA was associated with a significant increase in the risk of major bleeding (RR 1.77; 95% CI 1.09 to 2.87; p=0.02; figure 3). However, when all previous trials before the completion of the POINT trial were analysed, dual versus monotherapy was not associated with a significant increase in the risk of major bleeding (RR 1.46; 95% CI 0.77 to 2.75; p=0.25; figure 4).

Sensitivity analyses restricted to the nine doubleblind trials showed similar results for each outcome (online supplementary table 1) when compared with the full analyses.<sup>3 6 9 13 14 16 18 19 22</sup>

In the subgroup of the nine RCTs comparing clopidogrel plus aspirin versus aspirin alone, eight trials had dual therapy of  $\leq 3$  months (7 days to 3 months). When compared with aspirin alone, the combination of clopidogrel and aspirin was associated with a significant reduction in stroke recurrence (RR 0.69; 6

	Dual the	rapy	Monothe	erapy		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI Yea	M-H, Random, 95% Cl
1.1.1 AC vs A							
CARESS 2005	0	11	1	14	0.2%	0.42 [0.02, 9.34] 2005	· · · · · · · · · · · · · · · · · · ·
CHARISMA 2006	2	98	1	118	0.3%	2.41 [0.22, 26, 16] 2006	
FASTER (statin) 2007	9	100	12	99	2.2%	0.74 [0.33, 1.68] 2007	· · · · · · · · · · · · · · · · · · ·
FASTER (no statin) 2007	5	98	9	95	1.3%	0.54 [0.19, 1.55] 2007	· · · · · · · · · · · · · · · · · · ·
	0	46	2	52	0.2%		·
	212	2594	303	2586	53 1%	0.70 [0.59, 0.83] 2010	
	212	2004	303	2000	1 50/		
112014	5	204	10	200	1.5%	0.26 [0.11, 0.74] 2012	
He 2015	10	321	22	326	2.8%		
COMPRESS 2016	3	167	5	166	0.7%	0.60 [0.14, 2.46] 2016	
POINT 2018	116	2432	156	2449	27.1%	0.75 [0.59, 0.95] 2018	· · · · · · · · · · · · · · · · · · ·
Subtotal (95% CI)		6141		6191	89.4%	0.69 [0.61, 0.79]	•
Total events	362		529				
Heterogeneity: Tau <sup>2</sup> = 0.00;	Chi <sup>2</sup> = 6.92	2, df = 9	) (P = 0.65	); I <sup>2</sup> = 0	%		
Test for overall effect: Z = 5	.61 (P < 0.0	00001)					
1.1.2 AC vs C							
MATCH 2004	10	256	11	235	2.1%	0.83 [0.36, 1.93] 2004	
Subtotal (95% CI)		256		235	2.1%	0.83 [0.36, 1.93]	
Total events	10		11				
Heterogeneity: Not applicab	le						
Test for overall effect: $7 = 0$	42 (P = 0)	67)					
		.,					
ESPS 2 1006	2	32	4	79	0.5%	1 22 [0 22 6 22] 100	
	2	12	4	50	0.3%		
ESPRIT 2000	1	43	1	020	0.2%		
EARLY 2009	10	283	20	260	4.1%		
	10	300		390	4.9%	0.64 [0.37, 1.10]	$\bullet$
I otal events	19		31				
Heterogeneity: $Tau^2 = 0.00$ ;	$Chi^2 = 0.96$	6, df = 2	2 (P = 0.62)	); $I^2 = 0^4$	%		
Test for overall effect: Z = 1	.61 (P = 0.1	11)					
1.1.4 AD vs D							
Matias-Guiu 1987	0	69	0	40		Not estimable 1987	
ESPS 2 1996	2	32	4	79	0.5%	1.23 [0.24, 6.41] 1996	
Subtotal (95% Cl)		101		119	0.5%	1.23 [0.24, 6.41]	
Total events	2		4				
Heterogeneity: Not applicab	le						
Test for overall effect: Z = 0	.25 (P = 0.8	80)					
1.1.5 AD vs C							
PRoFESS 2009	11	672	20	688	2.8%	0.56 [0.27, 1.17] 2009	· · · · · · · · · · · · · · · · · · ·
Subtotal (95% CI)		672		688	2.8%	0.56 [0.27, 1.17]	
Total events	11		20				
Heterogeneity: Not applicab	nle		20				
Test for overall effect: $7 = 1$	$55 (P = 0)^{-1}$	12)					
	.00 (1 - 0.	12)					
1 1 6 Cilo+A vs A							
Nekomura 2012	1	20	2	20	0.20/	0.33 [0.04. 3.06] . 3013	
Nakamura 2012	1	30	3	30	0.3%		
		30		30	0.3%	0.33 [0.04, 3.06]	
I otal events	. 1		3				
Heterogeneity: Not applicab	ble						
Test for overall effect: Z = 0	.97 (P = 0.3	33)					
							▲
Total (95% Cl)		7566		7661	100.0%	0.69 [0.61, 0.78]	▼
Total events	405		598				
Heterogeneity: Tau <sup>2</sup> = 0.00;	Chi <sup>2</sup> = 9.3	5, df = 1	6 (P = 0.9	0); l <sup>2</sup> = (	0%		
Test for overall effect: Z = 6	.01 (P < 0.0	00001)					Eavours (dual therapy)] Eavours (monotherapy)
Test for subgroup difference	es: Chi <sup>2</sup> = 1	.48. df	= 5 (P = 0	92), l² =	0%		Favours [uuai merapyi] Favours [monomerapy]

**Figure 1** Comparison of dual antiplatelet versus monotherapy in acute ischaemic stroke or transient ischaemic attack on stroke recurrence. A, aspirin; C, clopidogrel; D, dipyridamole; M-H, Mantel-Haenszel method.

95% CI 0.61 to 0.79; p<0.001; figure 1), as well as the composite vascular events (RR 0.71; 95% CI 0.63 to 0.80; p<0.001; figure 2), and there was significant increase in major bleeding (RR 1.88; 95% CI 1.08 to 3.28; p=0.03; figure 3).

The other combinations of dual antiplatelet therapy analysed did not significantly reduce risks of stroke recurrence or the composite vascular events, as compared with monotherapy (figures 1 and 2), though there were no significant between-subgroup heterogeneities throughout the analyses. For trials comparing aspirin plus dipyridamole versus aspirin alone, there were no significant differences between dual antiplatelet therapy and monotherapy on stroke recurrence (RR 0.64; 95% CI 0.37 to 1.10; p=0.11; figure 1), composite vascular events (RR 0.67; 95% CI 0.42 to 1.07; p=0.09; figure 2) and major bleeding (RR 0.92; 95% CI 0.06 to 14.61; p=0.95; figure 3).

	Dual the	rapy	Monothe	erapy		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C	Year	r M-H, Random, 95% Cl
1.2.1 AC vs A								
CARESS 2005	1	11	2	14	0.2%	0.64 [0.07, 6.14]	2005	5
FASTER (no statin) 2007	12	98	21	95	2.9%	0.55 [0.29, 1.06]	2007	7
FASTER (statin) 2007	17	100	21	99	3.7%	0.80 [0.45, 1.43]	2007	7
CLAIR 2010	2	46	3	52	0.4%	0.75 [0.13, 4.31]	2010	0
CHANCE 2012	254	2584	356	2586	53.2%	0.71 [0.61, 0.83]	2012	2 •
Yi 2014	10	284	23	286	2.3%	0.44 [0.21, 0.90]	2014	4
COMPRESS 2016	4	167	6	166	0.8%	0.66 [0.19, 2.31]	2016	6
POINT 2018	121	2432	160	2449	23.2%	0.76 [0.61, 0.96]	2018	8
Subtotal (95% CI)		5722		5747	86.7%	0.71 [0.63, 0.80]		◆
Total events	421		592					
Heterogeneity: Tau <sup>2</sup> = 0.00;	Chi² = 2.8	2, df = 7	7 (P = 0.90	)); l <sup>2</sup> = 0	%			
Test for overall effect: Z = 5.	57 (P < 0.	00001)						
1.2.2 AC vs C								
MATCH 2004	15	256	17	235	2.7%	0.81 [0.41, 1.59]	2004	4
Subtotal (95% CI)		256		235	2.7%	0.81 [0.41, 1.59]		· • • • • • • • • • • • • • • • • • • •
Total events	15		17					
Heterogeneity: Not applicabl	e							
Test for overall effect: $Z = 0.0$	62 (P = 0.	54)						
	0	40	0	50		Net estimable	2000	6
ESPRIT 2006	0	43	0	52	F 00/		2006	
EARLY 2009	27	283	37	260	5.6%	0.67 [0.42, 1.07]	2009	9
Subiolal (95% CI)	07	320	27	312	5.0%	0.07 [0.42, 1.07]		•
l otal events	2/		37					
Test for overall effect: $Z = 1.0$	e 68 (P = 0.	09)						
10110								
1.2.4 AD VS D		•		•		Net estimable		
Subtotal (95% CI)		0		0		Not estimable		
l otal events	0		0					
Heterogeneity: Not applicabl	е							
lest for overall effect: Not ap	oplicable							
1.2.5 AD vs C								
PRoFESS 2009	26	672	35	688	5.0%	0.76 [0.46, 1.25]	2009	9
Subtotal (95% CI)		672		688	5.0%	0.76 [0.46, 1.25]		$\blacksquare$
Total events	26		35					
Heterogeneity: Not applicabl	е							
Test for overall effect: Z = 1.0	08 (P = 0.	28)						
1.2.6 Cilo+A vs A								
Subtotal (95% CI)		0		0		Not estimable		
Total events	0		0					
Heterogeneity: Not applicabl	е		•					
Test for overall effect: Not ap	oplicable							
Total (95% CI)		6976		6982	100.0%	0.72 [0.64, 0.80]		♦
Total events	489		681					
Heterogeneity: Tau <sup>2</sup> = 0.00;	Chi² = 3.0	9, df = 1	10 (P = 0.9	98); l² = (	0%			
Test for overall effect: Z = 5.9	92 (P < 0.	00001)						U.UT U.T 1 10 100
Test for subaroup differences	s: Chi <sup>2</sup> = (	).27. df :	= 3 (P = 0	.97). l² =	0%			Pavours [Dual merapy] Pavours [Monomerapy]

**Figure 2** Comparison of dual antiplatelet versus monotherapy in acute ischaemic stroke or transient ischaemic attack on composite outcome of stroke, transient ischaemic attack, acute coronary syndrome and all death. A, aspirin; C, clopidogrel; D, dipyridamole; M-H, Mantel-Haenszel method.

## DISCUSSION

Open access

In this updated systematic review and meta-analysis, 18 RCTs (15515 patients) evaluating dual versus mono antiplatelet therapy for acute non-cardioembolic IS or TIA within 3 days of ictus were included. We found that, compared with monotherapy, dual antiplatelet therapy was associated with a reduction in stroke recurrence, and composite vascular events, but with a significant increase in the risk of major bleeding. It is likely that good blood pressure control would markedly reduce the risk of intracranial haemorrhage, and diagnosis and treatment of *Helicobacter pylori* would markedly reduce the risk of major gastrointestinal haemorrhage.

A sensitivity analysis restricted to the nine double-blind RCTs showed similar results, which indicated that results of the present meta-analysis were generalisable. For each outcome, no significant between-study or between-subgroup heterogeneity in treatment effects of dual versus mono antiplatelet therapies was found. The effect of dual antiplatelet therapy on efficacy outcomes in the present meta-analysis was consistent with the results of POINT and CHANCE, while the effect on the safety outcome of

**Open access** 

	Dual the	rapy	Monothe	erapy		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C	Year	r M-H, Random, 95% Cl
1.3.1 AC vs A								
CARESS 2005	0	11	0	14		Not estimable	2005	5
CHARISMA 2006	1	98	0	118	2.3%	3.61 [0.15, 87,54]	2006	;
FASTER (statin) 2007	2	100	0	99	2.6%	4.95 [0.24, 101.82]	2007	,
FASTER (no statin) 2007	1	98	0	95	2.3%	2.91 [0.12, 70,54]	2007	,
CLAIR 2010	0	46	0	52	2.070	Not estimable	2010	
CHANCE 2012	7	2584	8	2586	22 7%	0.88 [0.32, 2.41]	2012	
Vi 2014	,	284	0	286	22.7 /0	Not estimable	2012	
He 2015	0 0	321	0	326		Not estimable	2014	
COMPRESS 2016	3	17/	0	178	2 7%	7 16 [0 37 137 60]	2010	Ś
POINT 2019	22	2422	10	2440	12.1 /0	1.10[0.37, 137.00]	2010	
Subtotal (95% CI)	23	6148	10	6203	42.5%	1 88 [1 08 3 28]	2010	
Total evente	27	0140	10	0200	/ 0.1 /0	1.00 [1.00, 0.20]		•
Hotorogonoity: $T_{0}u^2 = 0.00$	01 Chi2 - 201		10 : (D = 0.56	). 12 - 00	0/			
Test for everall effects 7 = 0.00,	0111 <sup>-</sup> – 3.90	5, ui – c	о (F – 0.50	), 1= − 0	/0			
Test for overall effect: $Z = Z$ .	22 (P = 0.0	J3)						
		050		005	4 00/	0 07 10 44 00 001	0004	
MATCH 2004	4	200	.1	235	4.9%	3.67 [0.41, 32.62]	2004	
		200		235	4.9%	3.07 [0.41, 32.02]		
l otal events	4		1					
Heterogeneity: Not applicabl	e							
l est for overall effect: $Z = 1$ .	17 (P = 0.2)	24)						
1.3.3 AD VS A	0	40	0	50			0000	、
ESPRIT 2006	0	43	0	52		Not estimable	2006	
EARLY 2009	1	283	1	260	3.0%	0.92 [0.06, 14.61]	2009	-
Subtotal (95% CI)		326		312	3.0%	0.92 [0.06, 14.61]		
Total events	1		1					
Heterogeneity: Not applicabl	е							
Test for overall effect: Z = 0.0	06 (P = 0.9	95)						
		•		•		Net estimately		
Subtotal (95% CI)		0		0		Not estimable		
Total events	0		0					
Heterogeneity: Not applicabl	e							
Test for overall effect: Not ap	plicable							
4.9.5.4.0								
1.3.5 AD VS C								
PROFESS 2009	6	672	4	688	14.7%	1.54 [0.44, 5.42]	2009	
Subtotal (95% CI)	-	672		688	14.7%	1.54 [0.44, 5.42]		
l otal events	6		4					
Heterogeneity: Not applicabl	e							
Test for overall effect: $Z = 0.0$	67 (P = 0.5	50)						
1.3.6 CIIO+A VS A					0.00/			
Nakamura 2012	0	38	1	38	2.3%	0.33 [0.01, 7.93]	2012	
Subtotal (95% CI)		38		38	2.3%	0.33 [0.01, 7.93]		
l otal events	0		1					
Heterogeneity: Not applicabl	e							
lest for overall effect: Z = 0.0	ов (P = 0.8	50)						
Total (05% CI)		7440		7476	100 0%	1 77 [1 00 2 07]		
Total (95% CI)	40	7440	25	1410	100.0%	1.77 [1.09, 2.07]		-
	40	o	25 	1. 12 - 00	7			
Therefore every: $1au^2 = 0.00;$	Unir = 5.73	5, ar = 8	P = 0.77	); 1~ = 09	70			0.01 0.1 1 10 100
Test for overall effect: $Z = 2$ .	55 (P = 0.0	JZ)	- 4 (D - 0	77) 12	00/			Favours [Dual therapy] Favours [Monotherapy]
I est for subaroup difference	s: Uni <sup>+</sup> = 1	.80. af :	-4(P=0)	( ( ).  * =	U%			

Figure 3 Comparison of dual antiplatelet versus monotherapy in acute ischaemic stroke or transient ischaemic attack on major bleeding. A, aspirin; C, clopidogrel; D, dipyridamole; M-H, Mantel-Haenszel method.

major bleeding was not consistent with the overall estimate of all previous trials before POINT.

Both CHANCE and POINT are large randomised, double-blind, placebo controlled, multicentre trials designed to investigate the efficacy and safety for clopidogrel plus aspirin versus aspirin alone in patients with acute minor IS or TIA. However, these two RCTs have some key differences in design. First, the enrolled populations are different. POINT enrolled patients within 12 hours of symptom onset mainly in American and European countries, while CHANCE only enrolled Chinese patients within 24 hours of symptom onset. Second, the antiplatelet therapy adopted in two trials is different. The treatment duration for dual antiplatelet therapy in POINT is 90 days, while the duration in CHANCE is 21 days. Also, the loading dose of clopidogrel in POINT is 600 mg, while the loading dose in CHANCE is 300 mg. Third, the primary efficacy outcome in POINT is a composite of major ischaemic events (IS, myocardial infarction or death from an ischaemic vascular event), while it is stroke (ischaemic or haemorrhagic) in CHANCE. Both trials showed the combination of clopidogrel with aspirin could reduce



Figure 4 Comparison of the separate POINT results and the overall estimates of dual antiplatelet versus monotherapy from all other trials included in the present meta-analysis on major bleeding; M-H, Mantel-Haenszel method.

the risk of stroke recurrence. Therefore, the results of POINT broaden the results of CHANCE to more diverse populations and care setting. However, there was a rate of major haemorrhage of 0.9% in combined antiplatelet group of POINT, significantly higher than 0.4% in the aspirin group of POINT, while the rate of moderate to severe haemorrhage in both groups of CHANCE is 0.3%. It seems that the smaller loading dose of clopidogrel and shorter treatment duration for combined clopidogrel plus aspirin may reduce the risk of haemorrhage. In addition, the frequency of CYP2C19 loss-of-function alleles in Asian population is higher than that in other populations, thus reducing the risk of haemorrhage in CHANCE by poor metabolism of clopidogrel.<sup>25 26</sup> These comparisons between POINT and CHANCE further suggest administering short-term dual antiplatelet therapy in the acute phase of IS or TIA is efficacious and safe.<sup>2</sup>

Another double-blind RCT included in the meta-analysis after November 2012, the COMPRESS trial (Combination of Clopidogrel and Aspirin for Prevention of Recurrence in Acute Atherothrombotic Stroke Study), randomised 358 patients with acute IS caused by large artery atherosclerosis within 48 hours of onset to clopidogrel plus aspirin or to aspirin alone for 30 days.<sup>22</sup> However, clopidogrel plus aspirin was not shown to be superior to aspirin alone in reducing new ischaemic lesion recurrence on MRI and clinical vascular events. Only 21.8% of patients were enrolled within 24 hours of onset and a loading dose of clopidogrel was not given, both of which might explain the negative results.

The recently published TARDIS trial (Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke), an international, open-label, blinded-endpoint, superiority RCT,<sup>28</sup> compared the safety and efficacy of intensive (combined aspirin, clopidogrel and dipyridamole) versus guideline-based (either clopidogrel alone or combined aspirin and dipyridamole) antiplatelet therapy in 3096 patients with acute non-cardioembolic IS or TIA within 48 hours of onset. The TARDIS trial was not included in the present meta-analysis, because it focused on triple versus mono or dual antiplatelet therapy. In TARDIS, triple antiplatelet therapy did not reduce the incidence and severity of recurrent stroke or TIA, but did significantly increase the risk of major bleeding, suggesting triple antiplatelet therapy should not be used.<sup>29</sup>

The SOCRATES trial (Acute Stroke or Transient Ischemic Attack Treated with Aspirin or Ticagrelor and Patient Outcomes) compared ticagrelor with aspirin in an international population, so it was not included in our meta-analysis.<sup>30</sup> The main SOCRATES analysis found that ticagrelor was not superior to aspirin in reducing the risk of major vascular events.<sup>31</sup> However, ticagrelor was superior to aspirin in large artery disease,<sup>32</sup> and there was a trend to superiority in Asian patients.<sup>33</sup> Two other relevant RCTs are ongoing. The international THALES trial (Acute Stroke or Transient Ischemic Attack Treated with Ticagrelor and

# <u>6</u>

ASA (acetylsalicylic acid) for Prevention of Stroke and Death) aimed to demonstrate the superior efficacy of ticagrelor plus aspirin versus aspirin alone in the prevention of subsequent stroke at 30 days in patients with IS or TIA (ClinicalTrials.gov number: NCT03354429). THALES will be covered in an updated meta-analysis like this one. In addition, the CSPS.com trial (Cilostazol Stroke Prevention Study for Antiplatelet Combination), a multicentre, openlabel RCT, is evaluating the efficacy and safety of dual antiplatelet therapy involving cilostazol for secondary stroke prevention.<sup>34</sup> A total of 4000 high-risk patients with non-cardioembolic IS will be randomised 8-180 days after onset to dual therapy with cilostazol plus aspirin or clopidogrel, or to aspirin or clopidogrel monotherapy for at least 1 year ( ClinicalTrials.gov identifier: NCT01995370). However, CSPS.com excluded patients within 3 days of ictus.

There are several limitations of the meta-analysis. First, included studies varied in characteristics, including the study population, stroke severity, antiplatelet medications, onset-to-treatment interval, treatment and follow-up durations, and other aspects. All of these factors could be potential confounders. Second, in some included studies, patients with IS or TIA within 3 days of ictus were not the primary target population and were a small portion of the primary study populations. Baseline characteristics might not be well balanced between dual and monotherapy groups in these studies.

#### **CONCLUSIONS**

Among patients with acute non-cardioembolic IS or TIA within 3 days of ictus, dual antiplatelet therapy was associated with a reduction in stroke recurrence, and composite vascular events, when compared with monotherapy. However, a significant increase in the risk of major bleeding was observed, which might attribute to higher loading dose of clopidogrel and longer treatment duration for dual therapy. The current data suggest administering short-term dual antiplatelet therapy in the acute phase of IS or TIA is efficacious and safe.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent Not required.

Provenance and peer review Commissioned; internally peer reviewed. Data sharing statement Additional data that supports the finding of this study is available from the online supplement.

#### Guest chief editor J David Spence

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/ licenses/by-nc/4.0/

#### REFERENCES

1. Coull AJ, Lovett JK, Rothwell PM. Oxford Vascular Study. Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organisation of

- services. *BMJ* 2004;328:326.
  Powers WJ, Rabinstein AA, Ackerson T, *et al.* 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. *Stroke* 2018;49:e46–e99.
- Markus HS, Droste DW, Kaps M, et al. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. *Circulation* 2005;111:2233–40.
- Wong KS, Chen C, Fu J, et al. Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial. *Lancet Neurol* 2010;9:489–97.
- Wang Y, Johnston SC. CHANCE Investigators. Rationale and design of a randomized, double-blind trial comparing the effects of a 3-month clopidogrel-aspirin regimen versus aspirin alone for the treatment of high-risk patients with acute nondisabling cerebrovascular event. *Am Heart J* 2010;160:380–6.
- Wang Y, Wang Y, Zhao X, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 2013;369:11–19.
- Wong KS, Wang Y, Leng X, *et al.* Early dual versus mono antiplatelet therapy for acute non-cardioembolic ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis. *Circulation* 2013;128:1656–66.
- Johnston SC, Easton JD, Farrant M, *et al.* Platelet-oriented inhibition in new TIA and minor ischemic stroke (POINT) trial: rationale and design. *Int J Stroke* 2013;8:479–83.
- Johnston SC, Easton JD, Farrant M, et al. Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. N Engl J Med 2018.
- GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673–82.
- Matías-Guiu J, Dávalos A, Picó M, et al. Low-dose acetylsalicylic acid (ASA) plus dipyridamole versus dipyridamole alone in the prevention of stroke in patients with reversible ischemic attacks. Acta Neurol Scand 1987;76:413–21.
- Kaye J. A trial to evaluate the relative roles of dipyridamole and aspirin in the prevention of deep vein thrombosis in stroke patients. Boehringer-Ingelheim: Bracknell, 1989.
- Diener HC, Cunha L, Forbes C, *et al*. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. *J Neurol Sci* 1996;143:1–13.
- Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. *Lancet* 2004;364:331–7.
- Chairangsarit P, Sithinamsuwan P, Niyasom S, et al. Comparison between aspirin combined with dipyridamole versus aspirin alone within 48 hours after ischemic stroke event for prevention of recurrent stroke and improvement of neurological function: a preliminary study. J Med Assoc Thai 2005;88 Suppl 3(Suppl 3):S148–54.
- Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706–17.
- Halkes PH, van Gijn J, Kappelle LJ, et al. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006;367:1665–73.
- Kennedy J, Hill MD, Ryckborst KJ, et al. Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol 2007;6:961–9.
- Bath PM, Cotton D, Martin RH, et al. Effect of combined aspirin and extended-release dipyridamole versus clopidogrel on functional outcome and recurrence in acute, mild ischemic stroke: PRoFESS subgroup analysis. Stroke 2010;41:732–8.
- Dengler R, Diener HC, Schwartz A, et al. Early treatment with aspirin plus extended-release dipyridamole for transient ischaemic attack or ischaemic stroke within 24 h of symptom onset (EARLY trial): a randomised, open-label, blinded-endpoint trial. *Lancet Neurol* 2010;9:159–66.
- Nakamura T, Tsuruta S, Uchiyama S. Cilostazol combined with aspirin prevents early neurological deterioration in patients with acute ischemic stroke: a pilot study. *J Neurol Sci* 2012;313:22–6.
- Hong KS, Lee SH, Kim EG, *et al.* Recurrent Ischemic Lesions After Acute Atherothrombotic Stroke: Clopidogrel Plus Aspirin Versus Aspirin Alone. *Stroke* 2016;47:2323–30.

- He F, Xia C, Zhang JH, et al. Clopidogrel plus aspirin versus aspirin alone for preventing early neurological deterioration in patients with acute ischemic stroke. J Clin Neurosci 2015;22:83–6.
- Yi X, Lin J, Wang C, et al. A comparative study of dual versus monoantiplatelet therapy in patients with acute large-artery atherosclerosis stroke. J Stroke Cerebrovasc Dis 2014;23:1975–81.
- Wang Y, Zhao X, Lin J, et al. Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack. JAMA 2016;316:70–8.
- Hasan MS, Basri HB, Hin LP, et al. Genetic polymorphisms and drug interactions leading to clopidogrel resistance: why the Asian population requires special attention. *Int J Neurosci* 2013;123:143–54.
- Pan Y, Jing J, Chen W, *et al.* Risks and benefits of clopidogrel-aspirin in minor stroke or TIA: Time course analysis of CHANCE. *Neurology* 2017.
- Krishnan K, Beridze M, Christensen H, et al. Safety and efficacy of intensive vs. guideline antiplatelet therapy in high-risk patients with recent ischemic stroke or transient ischemic attack: rationale and design of the Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke (TARDIS) trial (ISRCTN47823388). Int J Stroke 2015;10:1159–65.
- 29. Bath PM, Woodhouse LJ, Appleton JP, *et al*. Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or

aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial. *Lancet* 2018;391:850–9.

- Johnston SC, Amarenco P, Albers GW, et al. Acute Stroke or Transient Ischemic Attack Treated with Aspirin or Ticagrelor and Patient Outcomes (SOCRATES) trial: rationale and design. Int J Stroke 2015;10:n/a–8.
- Johnston SC, Amarenco P, Albers GW, et al. Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack. N Engl J Med 2016;375:35–43.
- Amarenco P, Albers GW, Denison H, et al. Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial. *Lancet Neurol* 2017;16:301–10.
- Wang Y, Minematsu K, Wong KS, *et al.* Ticagrelor in Acute Stroke or Transient Ischemic Attack in Asian Patients: From the SOCRATES Trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes). *Stroke* 2017;48:167–73.
- Toyoda K, Uchiyama S, Hoshino H, *et al.* Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS. com): a randomized, open-label, parallel-group trial. *Int J Stroke* 2015;10:253–8.

116